Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 300

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma

Open access
Wechsler, Michael E., Laviolette, Michel, Rubin, Adalberto S., Fiterman, Jussara, Lapa e Silva, Jose R., Shah, Pallav L., Fiss, Elie, Olivenstein, Ronald, Thomson, Neil C., Niven, Robert M., Pavord, Ian D., Simoff, Michael, Hales, Jeff B., McEvoy, Charlene, Slebos, Dirk-Jan, Holmes, Mark, Phillips, Martin J., Erzurum, Serpil C., Hanania, Nicola A., Sumino, Kaharu, Kraft, Monica, Cox, Gerard, Sterman, Daniel H., Hogarth, Kyle, Kline, Joel N., Mansur, Adel H., Louie, Brian E., Leeds, William M., Barbers, Richard G., Austin, John H.M., Shargill, Narinder S., Quiring, John, Armstrong, Brian, Castro, Mario·2013·Journal of Allergy and Clinical Immunology

Abstract

Background Bronchial thermoplasty (BT) has previously been shown to improve asthma control out to 2 years in patients with severe persistent asthma. Objective To assess effectiveness and safety of BT in asthma patients 5 years post therapy. Methods BT-treated subjects from the Asthma Intervention Research 2 (AIR2) Trial (ClinicalTrials.gov NCT01350414) were evaluated annually for 5 years to assess long-term safety of BT and durability of treatment effect. Outcomes assessed post-BT included severe exacerbations, adverse events, healthcare utilization, spirometry data, and high resolution computed tomography (HRCT) scans. Results 162/190 BT-treated subjects (85.3%) from the AIR2 Trial completed 5 years of follow-up. The proportion of subjects experiencing severe exacerbations and Emergency Room visits, and the rates of events in each of years 1 to 5 remained low and were less than those observed in the 12 months prior to BT treatment (average 5 year reduction in proportions: 44% for exacerbations and 78% for ER visits). Respiratory adverse events and respiratory-related hospitalizations remained unchanged in Years 2 through 5 as compared to the first year after BT. Pre-BD FEV1 values remained stable between years 1 and 5 after BT, despite a 17% reduction in average daily inhaled corticosteroid dose. HRCT scans from baseline to 5 years after BT showed no structural abnormalities that could be attributed to BT. Conclusions These data demonstrate the 5-year durability of the benefits of BT with regard to both asthma control (based on maintained reduction in severe exacerbations and ER visits for respiratory symptoms) and safety. BT has become an important addition to our treatment armamentarium and should be considered for patients with severe persistent asthma who remain symptomatic despite taking ICS (inhaled corticosteroids) and LABA (long-acting-β2-agonists).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jaci.2013.08.009

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 300

Metadata

Authors
Wechsler, M. E., Laviolette, M., Rubin, A. S., Fiterman, J., Lapa e Silva, J. R., Shah, P. L., Fiss, E., Olivenstein, R., Thomson, N. C., Niven, R. M., Pavord, I. D., Simoff, M., Hales, J. B., McEvoy, C., Slebos, D.-J., Holmes, M., Phillips, M. J., Erzurum, S. C., Hanania, N. A., Sumino, K., Kraft, M., Cox, G., Sterman, D. H., Hogarth, K., Kline, J. N., Mansur, A. H., Louie, B. E., Leeds, W. M., Barbers, R. G., Austin, J. H. M., Shargill, N. S., Quiring, J., Armstrong, B., & Castro, M.
Venue
Journal of Allergy and Clinical Immunology
Publisher
Elsevier BV
Published
2013-12
Volume
132
Issue
6
Pages
1295-1302.e3
ISSN
0091-6749 (ISSN-L)
OpenAlex
W2151256680
Cited by
300
References
14
FWCI
19.59
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma. https://app.cochat.ai/papers/10.1016/j.jaci.2013.08.009
The paper
Wechsler, M. E., Laviolette, M., Rubin, A. S., Fiterman, J., Lapa e Silva, J. R., Shah, P. L., Fiss, E., Olivenstein, R., Thomson, N. C., Niven, R. M., Pavord, I. D., Simoff, M., Hales, J. B., McEvoy, C., Slebos, D.-J., Holmes, M., Phillips, M. J., Erzurum, S. C., Hanania, N. A., . . . Castro, M. (2013). Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2013.08.009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.